The Pharma Data

JANUARY 6, 2021

. “We are leveraging our strengths in process development and manufacturing for a wide range of biopharmaceuticals such as antibodies, recombinant proteins, gene therapies and vaccines,” said Martin Meeson , chief executive officer at FUJIFILM Diosynth Biotechnologies.

Packaging 52

Packaging Small Molecule Production FDA Approval 52

Agency IQ

APRIL 8, 2024

While the SRP could be used to submit information on drugs and biological products, the only exception was for vaccines. Sponsors will have 24 months to get comfortable submitting IND safety reports in E2B(R3) format before compliance becomes mandatory in April 2026.

FDA 40

FDA Production Regulations Vaccine 40

The Pharma Data

SEPTEMBER 15, 2020

27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. Major revenue contributions through 2025 anticipated from Oncology, Vaccines, Rare Disease and Inflammation and Immunology. BNT162 mRNA-based Vaccine Program.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

Codon

SEPTEMBER 29, 2024

2026 Another lab, one with a greater appreciation for what machine learning could pull from noisy, high-throughput biological data, stumbled across the 2025 paper and discussed it in a Monday morning lab meeting. The longevity treatments that had emerged in the 2040s had become as commonplace as vaccines.

Engineering 144

Engineering Virus DNA Therapies 144

Drug Hunter

APRIL 24, 2023

Due to elimination of out of pocket patient costs for vaccines covered by Medicare/Medicaid access to adult vaccines will improve. million Medicare beneficiaries received a vaccine in 2022 and half of states did not cover all vaccines recommended by the Advisory Committee on Immunization Practices. For perspective, 4.1

Small Molecule 130

Small Molecule Drugs Biosimilars Vaccine 130

The Pharma Data

JUNE 2, 2022

Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines. The number of serotypes in current vaccines is limited due to the degree of immunological interference observed when using existing conjugation technologies.

Vaccine 52

Vaccine Immune Response Clinical Trials Disease 52

The Pharma Data

MAY 31, 2022

billion in potential development milestones Proposed acquisition provides access to next-generation 24-valent pneumococcal vaccine candidate in phase II development and highly innovative, MAPS TM technology Supports development of a strong portfolio of innovative vaccines and specialty medicines. GSK to pay $2.1

Vaccine 52

Vaccine Immune Response Clinical Trials Disease 52

FDA Law Blog: Biosimilars

FEBRUARY 4, 2025

With the current lapse in authorization, FDA may only award RPD PRVs for applications that have received an RPD designation before December 20, 2024, andunless reauthorized before thenmay not award any RPD PRVs after September 30, 2026. Below, we discuss some of its downstream impacts on the PRV landscape.

Disease 52

Disease Vaccine Therapies FDA 52

PLOS: DNA Science

MARCH 6, 2025

But efforts to continue development of mRNA-based bird flu vaccines are facing pushback from the new administration. Vaccine hesitancy may come to be its own epidemic. Also Not the Best Time to Cancel FDA Flu Vaccine Meeting Efforts to seemingly welcome bird flu continue. What About People?

Vaccine 102

Vaccine Virus FDA DNA 102